NCT07926867: A Pilot Multicentric Open Study Assessing the Efficacy and Safety of NEMOlizumab in Patients ≥ 12yo With Dystrophic Epidermolysis Bullosa
- State
- Not started
- Phase
- Phase 2 and Phase 3
- People
- 15 planned
- Started
- 31 Dec 2026
- Primary completion
- 31 Dec 2027
- Arms
- Nemolizumab will be administered as a 60 mg loading dose (two 30 mg injections) at Day 0, followed b
- Results
- None posted
- 9 Nov 2026: Trial registered